面对未知领域新型抗体药物的快速发展，机遇与挑战并存，华人抗体协会2024年年会，将于2024年5月11日（周六）在美国马萨诸塞州剑桥市(Cambridge, MA)召开，年会主题为：Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories。详情参见：
欢迎参加华人抗体协会2024年年会。
In recent years, the field of oncology has witnessed groundbreaking advancements, with immunotherapy emerging as a revolutionary approach. Among the diverse immunotherapeutic strategies, cell therapies including tumor-infiltrating lymphocyte (TIL) therapy, engineered T-cell receptor (TCR) therapy, chimeric antigen receptor (CAR) cell therapy hold potential to provide curative treatment options for cancer patients. These therapies can be either autologous or allogenic using genetically engineered effector cells. Another rapidly emerging strategy is the use of immune cell engagers, which direct immune effector cells against cancer. Immune cell engagers are considered as feasible and easy-to-deliver alternatives to adoptive cell therapy. Despite promises, significant challenges still need to be addressed, particularly in the treatment of solid tumors.
To underscore the significant impact of cell therapies and immune cell engagers in oncology, we are launching a call for papers for a collection on topic of ‘Cell Therapies and Cell Engagers against Cancer’. We encourage the submission of original research and review articles covering a broad range of topics in the fields of cell therapy and cell engagers.
This includes
TILs, TCR-T, CAR-T, natural killer (NK) cells, and other immune cell-based therapies.
We also invite contributions on
all formats of cell engagers that redirect T cells, NK cells, macrophages, and other immune cells.
The aim of this collection is to
deepen our understanding of these important areas, clarify their mechanisms of action, identify the challenges and opportunities they present, and accelerate the translation of these promising approaches into effective and affordable cancer treatments.
The Journal welcomes manuscript submission via the Antibody Therapeutics
online submission site
. Please view our
author guidelines
for further information on manuscript preparation and submission.
The deadline for submitting manuscripts for this collection is December 24, 2024. Please contact
[email protected]
if there are any questions.
Guest editors of this special issue are:
-
Dr. Baomei Wang
, Principal Scientific Researcher, Genentech
-
Dr. Chengbin Wu
, CEO and Founder of EpimAb Biotherapeutics Inc
Antibody Therapeutics
is published by Oxford University Press. As a peer-reviewed and open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, and methodology of therapeutic antibodies for the global scientific community. The Journal has been indexed by leading literature databases, such as Scopus (2022 CiteScore: 6.4) and PubMed.
华人抗体协会
是一个非营利、非政府的公益性组织，是第一个也是目前唯一一个全球性华人抗体专业组织。协会侧重关注治疗性抗体，并致力于创建一个全球性平台，以促进在治疗性抗体研发，生产以及商业化等领域的合作与交流。关于协会更多介绍请参阅：
华人抗体协会简介与发展简史
华人抗体协会与牛津大学出版社合作，出版同行评审英文专业期刊: Antibody Therapeutics。
Antibody Therapeutics网站：
https://academic.oup.com/abt
